Company Analysis
Sign in

iBio, Inc. (IBIO)

Nasdaq: IBIO · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2008
Full chart Alerts Compare
Grade3.4
◀ Past 2.1● Present 3.4▶ Future 4.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of iBio, Inc.

Nine metrics read from its own filings, by tense
Headline grade
3.4/10
◀ Past2.125% of the headline
● Present3.435% of the headline
▶ Future4.040% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

2.1/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.5/10

Has it survived what it has been through?

13 warning events since 2017; the latest 2025-08-01.

weight 22% of this tense · 15th percentile among 497 sector filers · read for itself

From the record

iBio, Inc.'s filings since 2017 show 13 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 9 times, the latest 2025-08-01); an auditor change (8-K item 4.01, the latest 2024-02-21); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2022-09-29) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.5/10

What has it actually done, year after year?

4 filed years; profitable in 0 of 4.

weight 45% of this tense · 35th percentile among 323 sector filers · read for its customers

From the record

iBio, Inc.'s 4 filed years say what it did: it rose in 1 of 2 years; the deepest fall was 75% from fiscal 2025 to fiscal 2026; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

  • the share of years revenue rosebottom 36% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak75.0%bottom 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
0.8/10

How has it treated the people who own it?

SI estimate 0.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 7th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 7% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: iBio, Inc.'s shareholder treatment is put at 0.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 7% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.4/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
4.8/10

Is it financially healthy right now?

ROE -39%: lost 39¢ per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar.

weight 45% of this tense · 47th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2026-06-30, iBio, Inc. lost about 39 cents for every dollar of shareholders' money. Leverage: it owed about 14 cents per dollar of assets, and net share issuance: its share count grew 891.1% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 22% of its family
  • return on equitytop 41% of its family
  • the share count against the year beforebottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
0.7/10

How strong is its position in its industry?

bottom 7% of 315 in its family; net margin -33044%.

weight 22% of this tense · 7th percentile among 315 sector filers · read for its customers

From the record

iBio, Inc.'s standing among 315 graded names in its industry family: revenue of $100 thousand in fiscal 2026 ranks in the bottom 8% by size; a net margin of -33044% ranks in the bottom 6% (its annual reports).

What it rests on

  • revenue against the family$100,000bottom 8% of its family
  • net margin-33044.0%bottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
3.4/10

What are the people in charge doing?

bottom 34% of 315 in its family for leadership; chief executive since 2023.

weight 33% of this tense · 34th percentile among 315 sector filers · read for its shareholders

From the record

iBio, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Brenner, Martin (Chief Executive Officer and Chief Scientific Officer, as filed), filing under that title since 2023-01-24, 3.8 years (bottom 40% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 3.7 years (bottom 22%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 40%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge6 in three years among 11 peoplebottom 40% of its family
  • the median years the people in charge have filed3.7 yearsbottom 22% of its family
  • the chief executive's years on the record3.8 yearsbottom 40% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

4.0/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
5.8/10

How much room does it have to grow?

top 43% of 273 in its family for room to expand.

weight 33% of this tense · 57th percentile among 273 sector filers · read for itself

From the record

iBio, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $56 million against no long-term debt tagged leaves 56.9% of its assets as net cash, top 29% of its family; cash from operations less capital spending is -23796% of revenue (bottom 6%); research spending of 19643% of revenue (top 4%) (its annual report).

What it rests on

  • cash less debt against assets56.9%top 29% of its family
  • cash from operations less capital spending against revenue-23796.0%bottom 6% of its family
  • research spending against revenue19643.0%top 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
3.5/10

What could actually drive growth from here?

bottom 35% of 306 in its family for growth drivers.

weight 45% of this tense · 35th percentile among 306 sector filers · read for its customers

From the record

iBio, Inc.'s growth drivers, from the filed years to fiscal 2026: the newest year grew -75% (bottom 8%); research spending grew 23.9% a year (top 20%); capital spending grew -53.5% a year (bottom 18%) (its annual reports). iBio, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • the newest year's revenue growth-75.0%bottom 8% of its family
  • three-year growth of research spending23.9%top 20% of its family
  • three-year growth of capital spending-53.5%bottom 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
2.5/10

Did its newest year beat what its own record pointed to?

bottom 25% of 233 in its family for expectations against reality.

weight 22% of this tense · 25th percentile among 233 sector filers · read for its shareholders

From the record

iBio, Inc.'s newest year against its own record: net income of $33 million against a prior three-year average of $36 million (bottom 46%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 4%) (its annual reports).

What it rests on

  • net income against the prior three years' average+9%bottom 46% of its family
  • net margin against its prior averagedown more than 100 pointsbottom 4% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton IBIO · research, not advice